Exscientia (EXAI) Stock Price, News & Analysis

Company Overview

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key Stats

• Today's Range: $4.49 to $4.85
• 50-Day Range: $4.69 to $5.96
• 52-Week Range: $3.80 to $6.49
• Volume: 1.51 million shs
• Average Volume: 617,576 shs
• Market Capitalization: $632.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

EXAI Stock Analysis - Frequently Asked Questions

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) issued its quarterly earnings data on Thursday, August, 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.05. The company had revenue of $5.60 million for the quarter. Exscientia had a negative trailing twelve-month return on equity of 49.10% and a negative net margin of 882.09%.

When did Exscientia IPO?

Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

Who are Exscientia's major shareholders?

Exscientia's top institutional shareholders include Blue Trust Inc., Blue Trust Inc., Group One Trading LLC and Citadel Advisors LLC.

What other stocks do shareholders of Exscientia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 3/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EXAI
• CIK: 1865408
• Web: www.exscientia.ai
• Phone: 44-0-18-6581-8941
• Fax: N/A
• Employees: 280
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $7.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +24.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-181,560,000.00
• Net Margins: -882.09%
• Pretax Margin: -904.93%
• Return on Equity: -49.10%
• Return on Assets: -33.13%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 4.54
• Quick Ratio: 4.54

Sales & Book Value

• Annual Sales: $25.60 million
• Price / Sales: 24.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.54 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 130,770,000
• Free Float: 109,324,000
• Market Cap: $632.93 million
• Optionable: Optionable
• Beta: 0.83